SpineSmith Acquires Rights to Tissue Genesis’ Stem Cell Isolating Technology for Diagnosis and Treatment of the Human Spine

SpineSmith Partners, LP acquired rights in spine for Tissue Genesis, Inc.’s adipose (fat) tissue derived cell technology. Tissue Genesis’ TGI 100™ cell isolation kits and TGI 1000™ automated cell isolation systems will process autologous (patient-derived) adipose tissue and isolate large quantities of regenerative cells, which can be utilized to treat a number of spine related diseases.

Adipose tissue has proven to be an abundant source of adult stem cells with the potential to form new bone and regenerate tissue. The Tissue Genesis technologies are currently being researched and developed to treat a number of spinal pathologies.

Under the terms of the agreement, SpineSmith Partners has licensed the rights to all of Tissue Genesis’s patents and technologies for use in the diagnosis and treatment of the human spine.

The stem cell therapy will be delivered to the patient via osteobiologic carriers currently on the market and under development. The ability to harvest and implant autologous cells in the operating room at the point-of-care should provide benefits to the surgeon, the patient and the healthcare system.

“This exciting new relationship with SpineSmith allows Tissue Genesis to move our therapeutic cell technologies into orthopedic markets,” said Anton C Krucky, President and CEO of Tissue Genesis. “SpineSmith’s extensive expertise with bone marrow stem cells, in both cell isolation and medical insurance reimbursement, provides a clear avenue of advancement of our adipose (fat) derived stem cells into this important market.”